Overview of the Regeneron Class Action Lawsuit
Investors are becoming increasingly aware of significant legal actions in the biotechnology sector, particularly regarding Regeneron Pharmaceuticals, Inc. Recently, Robbins Geller Rudman & Dowd LLP announced an opportunity for investors who suffered substantial losses from the company’s stock to take action. If you purchased or acquired Regeneron securities between November 2, 2023, and October 30, 2024, you are potential candidates for leading a class action lawsuit against the company.
Details of the Legal Claims
The class action complaint, known as Radtke v. Regeneron Pharmaceuticals, Inc., revolves around serious allegations against Regeneron and its executives, suggesting violations of the Securities Exchange Act of 1934. According to the lawsuit, Regeneron allegedly misled investors by making false statements and failing to disclose critical information that affected its securities.
Accusations of Misleading Practices
The accusations state that Regeneron engaged in questionable pricing practices related to their product Eylea, an injection for age-related macular degeneration. The lawsuit claims that the company improperly subsidized credit card fees to distributors, enabling them to sell Eylea at prices that were not reflective of true costs. Hence, the company allegedly inflated its reported sales figures while circumventing regulations meant to ensure proper pricing disclosures. These actions may have provided Regeneron with an unfair competitive edge.
Impact on Stock Prices
The repercussions of these allegations became apparent when on April 10, 2024, the U.S. Department of Justice filed a complaint against Regeneron for the very practices mentioned. Following this revelation, the stock price of Regeneron fell significantly, indicating that investor confidence had been shaken. This pattern continued when Regeneron reported disappointing third-quarter 2024 results on October 31, revealing only a 3% increase in sales and significant misses on analysts' expectations.
Class Action Participation
Under the Private Securities Litigation Reform Act of 1995, any investor who acquired securities during the specified class period has the right to seek appointment as the lead plaintiff. This role is crucial, as the lead plaintiff will act on behalf of other affected investors. Notably, participating in the class action does not require an investor to be a lead plaintiff. Even if you choose to support another plaintiff, you can still benefit from any potential recovery.
Understanding Robbins Geller's Role
Robbins Geller Rudman & Dowd LLP is recognized as a leading law firm specializing in representing investors affected by securities fraud. With a strong track record in securing substantial monetary relief for investors facing losses, the firm brings considerable experience to the table. Having recovered billions in securities-related litigation, they aim to achieve the best possible outcomes for investors harmed by misleading practices.
Contact Information for Concerned Investors
If you believe you qualify as a lead plaintiff or have questions regarding the class action, you can reach out to Robbins Geller attorneys, J.C. Sanchez and Jennifer N. Caringal. They can be contacted directly at 800-449-4900 or through email at info@rgrdlaw.com for further assistance.
Frequently Asked Questions
What is the Regeneron class action lawsuit about?
The class action lawsuit seeks to address allegations of misleading statements and pricing irregularities by Regeneron, particularly relating to their product Eylea.
Who can participate in this class action?
Any investor who purchased Regeneron securities during the class period from November 2, 2023, to October 30, 2024, can seek to be appointed as the lead plaintiff in the lawsuit.
What are the potential outcomes of participating in this lawsuit?
Participants may receive compensation if the class action lawsuit results in a favorable outcome for investors, regardless of whether they are the lead plaintiff or supporting plaintiffs.
How does one join the class action?
If you meet the criteria, you can contact Robbins Geller for guidance on how to formally join the class action lawsuit.
What should I do if I have further questions?
For any additional inquiries, you can contact the attorneys at Robbins Geller for professional advice and clarification related to your situation.
